Business
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections
OSAKA, Japan, April 07, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") presents new real-world data evaluating Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in adults with confirmed MBL-producing Enterobacterales infections at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, 17th-21st April, 2026.1
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":385,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/4b1607e106f792da6112f570ba35d57b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3YPEhiZrSUdUGIUInb8D2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTg3OQ--/https://media.zenfs.com/en/business-wire.com/4b1607e106f792da6112f570ba35d57b","width":385,"height":480}},"lazy":false},{"type":"text","content":"Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta lactamase (MBL)-producing pathogens1","length":223,"tagName":"p","attribs":{}},{"type":"text","content":"Carbapenem-resistant Enterobacterales pathogens are considered by the World Health Organization to be one of the most critical health threats2","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"OSAKA, Japan, April 07, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") presents new real-world data evaluating Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in adults with confirmed MBL-producing Enterobacterales infections at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, 17th-21st April, 2026.1","length":499,"tagName":"p"},{"type":"text","content":"Cefiderocol is for the treatment of seriously ill adult patients with complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain Gram-negative bacterial infections.3 See Fetroja U.S. full indications and important safety information below in the About Cefiderocol section.","length":376,"tagName":"p"},{"type":"text","content":"The CIRCE study was a retrospective, observational, multicenter chart review study conducted in Spain between January 2023 and April 2025, designed to describe the effectiveness and safety of real-world cefiderocol use in 232 adult patients with infections caused by MBL-producing Enterobacterales.1","length":299,"tagName":"p"},{"type":"text","content":"The analysis found 68% of p...